

# Lenoss Medical Oversubscribes \$4 Million Series A Financing

*Funding will accelerate commercialization, expand clinical evidence, and fuel innovative product development*



PROVIDENCE, RI, UNITED STATES, May 9, 2024 /EINPresswire.com/ -- [Lenoss Medical](https://www.Lenoss.com/), a pioneering medical device company developing the innovative

OsteoPearl biological allograft implant to address the critical need for osteoporotic vertebral compression fractures, today announced the successful closing of its Series A funding round. The Series A was oversubscribed with participation from Xcellerant Ventures, Highpoint Ventures, Vodia Capital, RightHill Ventures, and various Angel Investment Groups.



Their expertise in the healthcare sector and proven track record of supporting disruptive medical technologies will be invaluable as we advance the development and commercialization of OsteoPearl.”

*Dom Messerli, Lenoss Medical  
Founder & CEO*

The OsteoPearl implant is a novel biological allograft implant designed to stabilize painful vertebral compression fractures by providing a natural scaffold for physiological fracture repair. This technology has the potential to transform the way healthcare professionals approach treating osteoporotic vertebral compression fractures.

“We are thrilled to welcome aboard this new group of investors and to have closed and oversubscribed our Series A round,” said Dom Messerli, CEO and Founder of

Lenoss Medical. “Their expertise in the healthcare sector and proven track record of supporting disruptive medical technologies will be invaluable as we advance the development and commercialization of the OsteoPearl implant. This funding allows us to accelerate our commercialization, expand clinical evidence, and fuel our innovative product development to improve patient care.”


For more information on the OsteoPearl system visit [www.Lenoss.com](https://www.Lenoss.com/).

## About Lenoss

Lenoss Medical is a Providence, RI-based biomedical company focused on physiological repair of osteoporotic spinal fractures. The company's flagship product, the OsteoPearl system, is a biological allograft implant designed to provide natural bone where new bone is needed most.

###

Kevin Cooney  
Lenoss Medical  
marcomm@lenoss.com  
Visit us on social media:  
[LinkedIn](#)



OsteoPearl VBA System, made from 100% cortical bone, introduces structure to combat the effects of osteoporosis.



The OsteoPearl VBA System is the first and only fully biological solution for treating VCFs.

This press release can be viewed online at: <https://www.einpresswire.com/article/710284206>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.